Literature DB >> 27793819

Anatomical and functional outcomes following vitrectomy for advanced familial exudative vitreoretinopathy: a single surgeon's experience.

Mumin Hocaoglu1, Murat Karacorlu1, Isil Sayman Muslubas1, Mehmet Giray Ersoz1, Serra Arf1.   

Abstract

PURPOSE: To assess the anatomical and functional results of vitreoretinal surgery in patients with advanced familial exudative vitreoretinopathy (FEVR).
METHODS: Retrospective analysis of data for 10 eyes of 9 patients with advanced FEVR who underwent pars plana vitrectomy from March 1997 to May 2015 and had a follow-up of at least 12 months. The primary outcomes were final visual acuity (VA) and anatomical success.
RESULTS: The average age at the time of the surgery was 10.1±6.5 years (range 2 months-18 years). The mean follow-up period was 58.4±75.1 months. The male-to-female ratio was 7/2. The mean number of vitreoretinal operations was 1.5. At the last visit, 7 (70%) eyes had complete or partial retinal attachment. Preoperatively, the mean Snellen VA was 20/4000 (n=8), and in the remaining 2 (20%) eyes it was recorded as 'central, steady and maintained'. At final examination, the mean Snellen VA was 20/330 (n=7), and in the remaining 3 (30%) eyes it was recorded as light perception. At the final visit, 5 eyes (50%) had improved VA, 2 eyes (20%) showed stabilisation, and 3 eyes (30%) with total retinal detachment had a decrease in VA. No progression to glaucoma was observed and no enucleation was necessary.
CONCLUSIONS: Advanced FEVR in young children tends to be more aggressive, leading to severe complications. These cases are challenging and require special consideration. Despite surgery, disease-related complications remain high. However, surgical intervention for advanced FEVR might be of benefit in helping to preserve vision. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Retina; Treatment Surgery

Mesh:

Year:  2016        PMID: 27793819     DOI: 10.1136/bjophthalmol-2016-309526

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  [Familial exsudative vitreoretinopathy (FEVR) in childhood].

Authors:  A E Laubichler; P Laubichler; D Zapp; M Klopfer; M Ulbig
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

2.  Analysis of Predisposing Clinical Features for Worsening Traction After Treatment of Familial Exudative Vitreoretinopathy in Children.

Authors:  G Baker Hubbard; Alexa L Li
Journal:  Am J Ophthalmol       Date:  2020-07-21       Impact factor: 5.258

3.  The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy.

Authors:  Rui Zhang; Xin Sun; Bo Niu
Journal:  Exp Ther Med       Date:  2017-10-16       Impact factor: 2.447

4.  Diagnosis of complicated FEVR preoperatively and intra-/post-operatively: characteristics and risk factors for diagnostic timing.

Authors:  Fengjie Xia; Jiao Lyu; Ping Fei; Peiquan Zhao
Journal:  BMC Ophthalmol       Date:  2019-06-08       Impact factor: 2.209

5.  INTRAVITREAL RANIBIZUMAB TREATMENT FOR ADVANCED FAMILIAL EXUDATIVE VITREORETINOPATHY WITH HIGH VASCULAR ACTIVITY.

Authors:  Jiao Lyu; Qi Zhang; Yu Xu; Xiang Zhang; Ping Fei; Peiquan Zhao
Journal:  Retina       Date:  2021-09-01       Impact factor: 4.256

6.  ROP-like retinopathy in full/near-term newborns: A etiology, risk factors, clinical and genetic characteristics, prognosis and management.

Authors:  Limei Sun; Wenjia Yan; Li Huang; Songshan Li; Jia Liu; Yamei Lu; Manxiang Su; Zhan Li; Xiaoyan Ding
Journal:  Front Med (Lausanne)       Date:  2022-08-10

7.  Management and surgical outcomes of pediatric retinal detachment associated with familial exudative vitreoretinopathy - Our experience at a tertiary care ophthalmic center in North India.

Authors:  Vishal Agrawal; Sonal Kalia
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.